We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Comparison of Two Therapeutic Strategies of Dermoval in Treatment of Bullous Pemphigus

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00213421
Recruitment Status : Completed
First Posted : September 21, 2005
Last Update Posted : June 18, 2013
Sponsor:
Information provided by (Responsible Party):
University Hospital, Rouen

Tracking Information
First Submitted Date September 13, 2005
First Posted Date September 21, 2005
Last Update Posted Date June 18, 2013
Study Start Date August 2001
Actual Primary Completion Date October 2004   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures Not Provided
Original Primary Outcome Measures Not Provided
Change History
Current Secondary Outcome Measures Not Provided
Original Secondary Outcome Measures Not Provided
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title Comparison of Two Therapeutic Strategies of Dermoval in Treatment of Bullous Pemphigus
Official Title Not Provided
Brief Summary to compare efficacity and tolerance of two stratégies of dermoval application in treatment of bullous pemphigus.
Detailed Description Not Provided
Study Type Observational
Study Design Observational Model: Case-Only
Time Perspective: Prospective
Target Follow-Up Duration Not Provided
Biospecimen Not Provided
Sampling Method Non-Probability Sample
Study Population patients with compatible bullous pemphigoid clinical exam
Condition Bullous Pemphigoid
Intervention Drug: Dermoval
group 1 elevated corticosteroids : attack treatment 2 tubes of 10g (4t/d) decreasing treatment : one month: 2 tubes/J (2t/d); 2 months : 2 tubes 1d sur 2 (1d/j); 4 months : 2 tubes 2 fois /week (0,6t/d); 4 months : 2 tubes 1 fois /week (0,3t/d)fois /week (0,3t/d) group 2 low corticosteroids : for paucibullous form with weight < 45kg attack treatment 1 tubes of 10g (1t/d)decreasing treatment 1 month : 1 tube every 2d (0,5t/d; 1 month : 1 tubes 2 fois /week (0,3t/d) 1 month : 1 tubes 1 fois/week (0,15t/d); for paucibullous form with weight > 45kg or for multibullous form with weight < 45kg attack treatment 2 tubes of 10g (2t/d)decreasing treatment 1 month : 2 tubes every 2j (1t/d; 1 month : 2 tubes 2 fois /week (0,6t/d) 1 month : 2 tubes 1 fois /week (0,3t/d)and for multibullous form attack with weigth > 45kg treatment 3 tubes of 10g (3t/d)decreasing treatment 1 month : 3 tubes every 2days (1,5t/d) 1 month : 3 tubes 2 fois /week (1t/j)1 mois : 3 tubes 1 fois /week (0,45t/d)
Study Groups/Cohorts
  • 1
    Intervention: Drug: Dermoval
  • 2
    Intervention: Drug: Dermoval
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status Completed
Actual Enrollment
 (submitted: March¬†19,¬†2007)
330
Original Enrollment Not Provided
Actual Study Completion Date November 2008
Actual Primary Completion Date October 2004   (Final data collection date for primary outcome measure)
Eligibility Criteria

Inclusion Criteria:

  • age > 18
  • immunoflurescence, histological exam, predictive value according to bullous pemphigus diagnostic
  • consentment patient

Exclusion Criteria:

  • age < 18
  • no consentment
  • localized bullous pemphigus (<400cm2)
  • linear IgA pemphigus
  • corticothérapy, immunotherapy
  • pregnant woman pemphigus
Sex/Gender
Sexes Eligible for Study: All
Ages 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers No
Contacts Contact information is only displayed when the study is recruiting subjects
Listed Location Countries France
Removed Location Countries  
 
Administrative Information
NCT Number NCT00213421
Other Study ID Numbers 2000/014/HP
Has Data Monitoring Committee Not Provided
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement Not Provided
Current Responsible Party University Hospital, Rouen
Original Responsible Party Not Provided
Current Study Sponsor University Hospital, Rouen
Original Study Sponsor Same as current
Collaborators Not Provided
Investigators
Principal Investigator: Pascal Joly, MD-PHD UH Rouen
PRS Account University Hospital, Rouen
Verification Date June 2013